Pharmaceutical Company In-house Research and Licensing Transaction Review

Authors

Abstract

Background:​ Pharmaceutical in-house research and licensing deals are effective means of widespread production of drugs to the public. These transactions follow a normalized procedure requiring upfront payments between a buying company to work either collaboratively with a small to medium sized selling company or buying the right of a product completely. Licensing a novel pharmaceutical drug goes through several clinical phases, and transaction deals can involve royalty and/or milestone payments along the research and clinical trial process.

Methods​: Data was collected through analysis of pharmaceutical licensing market deals via online databases and extracted to a data sheet for examination. Trends were highlighted after analyzing upfront payment values, royalty sales, milestone payments and total transaction deal value.

Results​: Total milestone payments averaged at USD $639.1 million, and total royalty payments averaged at USD $899.77 million. Average total deal values is USD $1445.18 million. Correlation coefficients between: (1) upfront and milestone payments r = 0.155; (2) upfront payments and royalty payments r = 0.188; and (3) upfront payments and total deal value r = 0.604. Most transactions are a small/medium enterprise selling to big pharmaceutical companies (32%) or a big pharmaceutical company selling to a small/medium enterprise (32%). 27% of deals are between big pharmaceutical companies, and 9% of deals are between small/medium enterprises.

Conclusion:​ There is a positive correlation between upfront payment costs with milestone/royalty costs and total deal value (n=25). Small or medium enterprises are beginning to take a large sector of the transaction business as their in-house research licensing grows more appealing for market distribution.

Keywords:

Licensing, pharmaceuticals, transaction

Downloads

Download data is not yet available.

References

Schuhmacher, A., Gassmann, O. and Hinder, M. (2016). Changing R&D models in research-based pharmaceutical companies. Journal of Translational Medicine, 14(1). Retrieved March 12, 2021, from https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-016-0838-4

Arnold, K., Coia, A., Saywell, S., Smith, T., Minick, S. and Löffler, A. (2002). Value drivers in licensing deals. Nature Biotechnology, 20(11), pp.1085-1089. Retrieved March 12, 2021, from https://go.gale.com/ps/anonymous?id=GALE%7CA190106398&sid=googleScholar&v=2.1&it=r&linkaccess=abs&issn=10870156&p=AONE&sw=w

Pharma 2020: The vision. (2020). Retrieved March 12, 2021 from https://www.vph-institute.org/upload/pwc-pharma2020-report_5192450c305bd.pdf

Simonet, D, 2002. Licensing Agreements in the Pharmaceutical Industry. Journal of Medical Marketing, 2(4), 329-341. Retrieved March 12, 2021, from https://journals.sagepub.com/doi/10.1057/palgrave.jmm.5040090

F, A. (2019). Why pharmaceutical companies are on a shopping binge. Retrieved March 12, 2021, from https://www.economist.com/the-economist-explains/2019/01/14/why-pharmaceutical-companies-are-on-a-shopping-binge

O’Connell, K. E. (2014). The premium of a big pharma license deal. Retrieved March 12, 2021, from https://pubmed.ncbi.nlm.nih.gov/25004224/

The growing pharmaceuticals market: Expert forecasts and analysis. (2018). Retrieved March 12, 2021, from https://blog.marketresearch.com/the-growing-pharmaceuticals-market-expert-forecasts-and-analysis

Business insights, analysis & perspectives. (2019). Retrieved March 12, 2021, from https://www2.deloitte.com/insights/us/en.html

Wong, C. H., Siah, K. W., & Lo, A. W. (2019). Estimation of clinical trial success rates and related parameters. Retrieved March 12, 2021, from https://academic.oup.com/biostatistics/article/20/2/273/4817524

About Dillon Capital Strategies. (2019). Retrieved March 12, 2021, from http://dilloncapital.com/

Torjesen, I. (2015). Drug development: the journey of a medicine from lab to shelf. Pharmaceutical Journal. Retrieved March 12, 2021, from https://www.pharmaceutical-journal.com/publications/tomorrows-pharmacist/drug-de velopment-the-journey-of-a-medicine-fro m-lab-to-shelf/20068196.article?firstPass=false

Sullivan, T. (2019). A Tough Road: Cost To Develop One New Drug Is $2.6 Billion; Approval Rate for Drugs Entering Clinical Development is Less Than 12%. Policymed.com. Retrieved March 12, 2021, from https://www.policymed.com/2014/12/a-tou gh-road-cost-to-develop-one-new-drug-is- 26-billion-approval-rate-for-drugs-entering -clinical-de.html

Kessel, M. and Hall, S. (2006). Avoiding premature licensing. Nature Reviews Drug Discovery, 5(12), pp.985-986. Retrieved March 12, 2021 from https://www.nature.com/articles/nrd2203

Urquhart, L. and Elmhirst, E. (2018). Oncology continues to reign in the licensing world. Evaluate.com. Retrieved March 12, 2021 from https://www.evaluate.com/vantage/articles/8. FIGURES and LEGENDSdata-insights/other-data/oncology-continues-reign-licensing-world-0

Iam-media.com. (2018). Oncology drives major pharma deals while immuno-oncology patent activity soars. IAM. Retrieved March 12, 2021 from https://www.iam-media.com/market-developments/oncology-drives-major-pharma-deals-while-immuno-oncology-patent-activity

Pharmaceutical Technology (2017). Pharma licensing deals 2016/2017 comparison. Pharmaceutical Technology. Retrieved March 12, 2021 from https://www.pharmaceutical-technology.co m/research-reports/researchreportpharma-licensing-deals-20162017-comparison-5794903/

Staton, T. (2017). AstraZeneca, Merck team up on Lynparza combos in collaboration worth up to $8.5B. FiercePharma. Retrieved March 12, 2021 from https://www.fiercepharma.com/pharma/astrazeneca-merck-team-up-lynparza-combos-collab-worth-up-to-8-5b

Life science leader. (2019). Retrieved March 12, 2021, from https://www.lifescienceleader.com/

Comparing 3 Popular Pricing Models: Fixed-Price, Time & Materials, and Milestone. Medium. 2019. Retrieved March 12, 2021 from https://medium.com/swlh/comparing-3-popular-pricing-models-fixed-price-time-materials-and-milestone-6b986021f2ed

Downloads

Published

2021-04-03

Issue

Section

Review Article

How to Cite

Drago, T., Cahill, K., Grealy, A., Lucey, K., & Mahmoud, M. (2021). Pharmaceutical Company In-house Research and Licensing Transaction Review. Advanced Journal of Social Science, 8(1), 77–85. Retrieved from https://journals.aijr.org/index.php/ajss/article/view/3538